Myriad Genetics, Inc.

Myriad Genetics is a molecular diagnostics and precision medicine company that develops and commercializes molecular tests. These tests help patients and providers uncover genetic insights by assessing the risk of developing disease or disease progression and guiding treatment decisions. The company focuses on medical specialties where molecular insights can improve patient care, support earlier detection, enable more precise treatment, and contribute to lowering healthcare costs. Myriad Genetics' business strategy aims to engage with providers and patients throughout their journey, believing there are growth opportunities in addressing healthcare needs through molecular diagnostic testing and precision medicine solutions. The company's long-term growth strategy leverages its reputation for high-quality tests and customer service, extensive commercial reach in community medicine, and investments in science, innovation, and technology-enabled operations. The strategic intent is to accelerate profitable growth by focusing on three areas: providing a comprehensive testing menu for the Cancer Care Continuum (CCC) market with a priority for high-growth applications; growing Prenatal Health and Mental Health revenues at or above market growth; and delivering sustained profitable growth through financial and operational discipline. The company plans to expand adoption of its testing portfolio and integrate precision medicine solutions into clinical workflows across Cancer Care Continuum, Prenatal Health, and Mental Health. In the United States, more than two million new cancer cases are diagnosed, and more than eighteen million survivors exist in 2025.